Nurix Therapeutics Inc.
08/22/2025 | Press release | Distributed by Public on 08/22/2025 14:02
Management Change/Compensation (Form 8-K)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers..
(b)
On August 19, 2025, Lori A. Kunkel, M.D., advised the board of directors (the "Board") of Nurix Therapeutics, Inc. (the "Company") that she would resign as a Class III director of the Board, and as chair of the Clinical and Commercialization Committee of the Board (the "Clinical and Commercialization Committee"), and as a member of the Clinical and Commercialization Committee and the Compensation Committee of the Board, effective September 1, 2025. Dr. Kunkel's decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
In connection with Dr. Kunkel's resignation, the Board appointed Roy D. Baynes, MB.Bch., M.Med., Ph.D., a member of the Board and the Clinical and Commercialization Committee, to serve as chair of the Clinical and Commercialization Committee, effective as of September 1, 2025.
2
Nurix Therapeutics Inc. published this content on August 22, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on August 22, 2025 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]